Dipeptidyl peptidase 4 (DPP4)/CD26 truncates certain proteins, and this posttranslational modification can influence their activity. Truncated (T) colony-stimulating factors (CSFs) are decreased in potency for stimulating proliferation of hematopoietic progenitor cells (HPCs). T-CXCL12, a modified chemokine, is inactive as an HPC chemotactic, survival, and enhancing factor for replating or ex-vivo expansion of HPCs. Moreover, T-CSFs and T-CXCL12 specifically downmodulates the positively acting effects of their own full-length molecule. Other chemokines have DPP4 truncation sites. In the present study, we evaluated effects of DPP4 inhibition (by Diprotin A) or gene deletion of HPC on chemokine inhibition of multicytokine-stimulated HPC, and on chemokine-enhancing effects on single CSF-stimulated HPC proliferation, as well as effects of DPP4 treatment of a number of chemokines. Myelosuppressive effects of chemokines with, but not without, a DPP4 truncation site were greatly enhanced in inhibitory potency by pretreating target bone marrow (BM) cells with Diprotin A, or by assaying their activity on dpp4/cd26−/− BM cells. DPP4 treatment of myelosuppressive chemokines containing a DPP4 truncation site produced a nonmyelosuppressive molecule, but one which had the capacity to block suppression by that unmodified chemokine both in vitro and in vivo. Additionally, DPP4 treatment ablated the single cytokine-stimulated HPC-enhancing activity of CCL3/MIP-1α and CCL4/MIP-1β, and blocked the enhancing activity of each unmodified molecule, in vitro and in vivo. These results highlight the functional posttranslational modulating effects of DPP4 on chemokine activities, and information offering additional biological insight into chemokine regulation of hematopoiesis.
Get full access to this article
View all access options for this article.
References
1.
ShaheenM and Broxmeyer.HE (2011). Hematopoietic cytokines and growth factors. In: Cord Blood Biology, Transplantation, Banking, and Regulation. BroxmeyerHE, ed. AABB Press, Bethesda, MD, pp 35–74.
RasmussenHB, BrannerS, WibergFC and WagtmannN. (2003). Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol, 10:19–25.
4.
AertgeertsK, YeS, TennantMG, KrausML, RogersJ, SangBC, SkeneRJ, WebbDR and PrasadGS. (2004). Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation. Protein Sci, 13:412–421.
5.
ChristophersonKW, HangocG and BroxmeyerHE. (2002). Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J Immunol, 169:7000–7008.
6.
ChristophersonKW, HangocG, MantelCR and BroxmeyerHE. (2004). Modulation of hematopoietic stem cell homing and engraftment by CD26. Science, 305:1000–1003.
CampbellTB, HangocG, LiuY, PollokK and BroxmeyerHE. (2007). Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. Stem Cells Dev, 16:347–354.
9.
ChristophersonKW, PaganessiLA, NapierS and PorechaNK. (2007). CD26 inhibition on CD34+ or lineage- human umbilical cord blood donor hematopoietic stem cells/hematopoietic progenitor cells improves long-term engraftment into NOD/SCID/Beta2null immunodeficient mice. Stem Cells Dev, 16:355–360.
10.
PorechaNK, EnglishK, HangocG, BroxmeyerHE and ChristophersonKW. (2006). Enhanced functional response to CXCL12/SDF-1 through retroviral overexpression of CXCR4 on M07e cells: implications for hematopoietic stem cell transplantation. Stem Cells Dev, 15:325–333.
11.
BroxmeyerHE, CooperS, KohliL, HangocG, LeeY, MantelC, ClappDW and KimCH. (2003). Transgenic expression of stromal cell-derived factor-1/CXC chemokine ligand 12 enhances myeloid progenitor cell survival/antiapoptosis in vitro in response to growth factor withdrawal and enhances myelopoiesis in vivo. J Immunol, 170:421–429.
12.
BroxmeyerHE, KohliL, KimCH, LeeY, MantelC, CooperS, HangocG, ShaheenM, LiX and ClappDW. (2003). Stromal cell-derived factor-1/CXCL12 directly enhances survival/antiapoptosis of myeloid progenitor cells through CXCR4 and G(alpha)i proteins and enhances engraftment of competitive, repopulating stem cells. J Leukoc Biol, 73:630–638.
13.
BroxmeyerHE, MejiaJA, HangocG, BareseC, DinauerM and CooperS. (2007). SDF-1/CXCL12 enhances in vitro replating capacity of murine and human multipotential and macrophage progenitor cells. Stem Cells Dev, 16:589–596.
14.
OuX, O'LearyHA and BroxmeyerHE. (2013). Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types. Blood, 122:161–169.
15.
O'LearyH, OuX and BroxmeyerHE. (2013). The role of dipeptidyl peptidase 4 in hematopoiesis and transplantation. Curr Opin Hematol, 20:314–319.
16.
ProostP, MentenP, StruyfS, SchutyserE, De MeesterI and Van DammeJ. (2000). Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist. Blood, 96:1674–1680.
17.
De MeesterI, DurinxC, BalG, ProostP, StruyfS, GoossensF, AugustynsK and ScharpeS. (2000). Natural substrates of dipeptidyl peptidase IV. Adv Exp Med Biol, 477:67–87.
18.
De MeesterI, LambeirAM, ProostP and ScharpeS. (2003). Dipeptidyl peptidase IV substrates. An update on in vitro peptide hydrolysis by human DPPIV. Adv Exp Med Biol, 524:3–17.
19.
GewirtzAM, CalabrettaB, RucinskiB, NiewiarowskiS and XuWY. (1989). Inhibition of human megakaryocytopoiesis in vitro by platelet factor 4 (PF4) and a synthetic COOH-terminal PF4 peptide. J Clin Invest, 83:1477–1486.
20.
GrahamGJ, WrightEG, HewickR, WolpeSD, WilkieNM, DonaldsonD, LorimoreS and PragnellIB. (1990). Identification and characterization of an inhibitor of haemopoietic stem cell proliferation. Nature, 344:442–444.
21.
BroxmeyerHE, SherryB, LuL, CooperS, OhKO, Tekamp-OlsonP, KwonBS and CeramiA. (1990). Enhancing and suppressing effects of recombinant murine macrophage inflammatory proteins on colony formation in vitro by bone marrow myeloid progenitor cells. Blood, 76:1110–1116.
22.
MazeR, SherryB, KwonBS, CeramiA and BroxmeyerHE. (1992). Myelosuppressive effects in vivo of purified recombinant murine macrophage inflammatory protein-1 alpha. J Immunol, 149:1004–1009.
23.
DunlopDJ, WrightEG, LorimoreS, GrahamGJ, HolyoakeT, KerrDJ, WolpeSD and PragnellIB. (1992). Demonstration of stem cell inhibition and myeloprotective effects of SCI/rhMIP1 alpha in vivo. Blood, 79:2221–2225.
24.
BroxmeyerHE, SherryB, CooperS, LuL, MazeR, BeckmannMP, CeramiA and RalphP. (1993). Comparative analysis of the human macrophage inflammatory protein family of cytokines (chemokines) on proliferation of human myeloid progenitor cells. Interacting effects involving suppression, synergistic suppression, and blocking of suppression. J Immunol, 150:3448–3458.
25.
LuL, XiaoM, GrigsbyS, WangWX, WuB, ShenRN and BroxmeyerHE. (1993). Comparative effects of suppressive cytokines on isolated single CD34(3+) stem/progenitor cells from human bone marrow and umbilical cord blood plated with and without serum. Exp Hematol, 21:1442–1446.
26.
KellerJR, BartelmezSH, SitnickaE, RuscettiFW, OrtizM, GooyaJM and JacobsenSE. (1994). Distinct and overlapping direct effects of macrophage inflammatory protein-1 alpha and transforming growth factor beta on hematopoietic progenitor/stem cell growth. Blood, 84:2175–2181.
27.
MayaniH, LittleMT, DragowskaW, ThornburyG and LansdorpPM. (1995). Differential effects of the hematopoietic inhibitors MIP-1 alpha, TGF-beta, and TNF-alpha on cytokine-induced proliferation of subpopulations of CD34+ cells purified from cord blood and fetal liver. Exp Hematol, 23:422–427.
28.
GewirtzAM, ZhangJ, RatajczakJ, RatajczakM, ParkKS, LiC, YanZ and PonczM. (1995). Chemokine regulation of human megakaryocytopoiesis. Blood, 86:2559–2567.
29.
BroxmeyerHE, CooperS, HagueN, BenningerL, SarrisA, CornettaK, Vadhan-RajS, HendrieP and MantelC. (1995). Human chemokines: enhancement of specific activity and effects in vitro on normal and leukemic progenitors and a factor-dependent cell line and in vivo in mice. Ann Hematol, 71:235–246.
30.
BroxmeyerHE, CooperS, CacalanoG, HagueNL, BailishE and MooreMW. (1996). Involvement of interleukin (IL) 8 receptor in negative regulation of myeloid progenitor cells in vivo: evidence from mice lacking the murine IL-8 receptor homologue. J Exp Med, 184:1825–1832.
31.
GaoJL, WynnTA, ChangY, LeeEJ, BroxmeyerHE, CooperS, TiffanyHL, WestphalH, Kwon-ChungJ and MurphyPM. (1997). Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1. J Exp Med, 185:1959–1968.
32.
BoringL, GoslingJ, ChensueSW, KunkelSL, FareseRVJr., BroxmeyerHE and CharoIF. (1997). Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest, 100:2552–2561.
33.
BroxmeyerHE, OraziA, HagueNL, SledgeGWJr., RasmussenH and GordonMS. (1998). Myeloid progenitor cell proliferation and mobilization effects of BB10010, a genetically engineered variant of human macrophage inflammatory protein-1alpha, in a phase I clinical trial in patients with relapsed/refractory breast cancer. Blood Cells Mol Dis, 24:14–30.
34.
BroxmeyerHE, KimCH, CooperSH, HangocG, HromasR and PelusLM. (1999). Effects of CC, CXC, C, and CX3C chemokines on proliferation of myeloid progenitor cells, and insights into SDF-1-induced chemotaxis of progenitors. Ann N Y Acad Sci, 872:142–162.
35.
ReidS, RitchieA, BoringL, GoslingJ, CooperS, HangocG, CharoIF and BroxmeyerHE. (1999). Enhanced myeloid progenitor cell cycling and apoptosis in mice lacking the chemokine receptor, CCR2. Blood, 93:1524–1533.
36.
BroxmeyerHE, CooperS, HangocG, GaoJL and MurphyPM. (1999). Dominant myelopoietic effector functions mediated by chemokine receptor CCR1. J Exp Med, 189:1987–1992.
37.
KimCH, QuCK, HangocG, CooperS, AnzaiN, FengGS and BroxmeyerHE. (1999). Abnormal chemokine-induced responses of immature and mature hematopoietic cells from motheaten mice implicate the protein tyrosine phosphatase SHP-1 in chemokine responses. J Exp Med, 190:681–690.
38.
KimCH, HangocG, CooperS, HelgasonCD, YewS, HumphriesRK, KrystalG and BroxmeyerHE. (1999). Altered responsiveness to chemokines due to targeted disruption of SHIP. J Clin Invest, 104:1751–1759.
39.
SarrisAH, BroxmeyerHE, WirthmuellerU, KarasavvasN, CooperS, LuL, KruegerJ and RavetchJV. (1993). Human interferon-inducible protein 10: expression and purification of recombinant protein demonstrate inhibition of early human hematopoietic progenitors. J Exp Med, 178:1127–1132.
40.
DalyTJ, LaRosaGJ, DolichS, MaioneTE, CooperS and BroxmeyerHE. (1995). High activity suppression of myeloid progenitor proliferation by chimeric mutants of interleukin 8 and platelet factor 4. J Biol Chem, 270:23282–23292.
41.
HromasR, KimCH, KlemszM, KrathwohlM, FifeK, CooperS, Schnizlein-BickC and BroxmeyerHE. (1997). Isolation and characterization of exodus-2, a novel C-C chemokine with a unique 37-amino acid carboxyl-terminal extension. J Immunol, 159:2554–2558.
42.
BroxmeyerHE, CooperS, HangocG and KimCH. (2005). Stromal cell-derived factor-1/CXCL12 selectively counteracts inhibitory effects of myelosuppressive chemokines on hematopoietic progenitor cell proliferation in vitro. Stem Cells Dev, 14:199–203.
43.
BroxmeyerHE, SherryB, LuL, CooperS, CarowC, WolpeSD and CeramiA. (1989). Myelopoietic enhancing effects of murine macrophage inflammatory proteins 1 and 2 on colony formation in vitro by murine and human bone marrow granulocyte/macrophage progenitor cells. J Exp Med, 170:1583–1594.
ZlotnikA and YoshieO. (2012). The chemokine superfamily revisited. Immunity, 36:705–716.
46.
AllenSJ, CrownSE and HandelTM. (2007). Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol, 25:787–820.
47.
BachelerieF, Ben-BaruchA, BurkhardtAM, CombadiereC, FarberJM, GrahamGJ, HorukR, Sparre-UlrichAH, LocatiM, et al. (2014). International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev, 66:1–79.
48.
YounBS, MantelC and BroxmeyerHE. (2000). Chemokines, chemokine receptors and hematopoiesis. Immunol Rev, 177:150–174.
49.
BroxmeyerHE and KimCH. (1999). Regulation of hematopoiesis in a sea of chemokine family members with a plethora of redundant activities. Exp Hematol, 27:1113–1123.
50.
BroxmeyerHE. (2001). Regulation of hematopoiesis by chemokine family members. Int J Hematol, 74:9–17.
51.
FaragSS, SrivastavaS, Messina-GrahamS, SchwartzJ, RobertsonMJ, AbonourR, CornettaK, WoodL, SecrestA, et al. (2013). In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev, 22:1007–1015.
52.
Velez de MendizabalN, StrotherRM, FaragSS, BroxmeyerHE, Messina-GrahamS, ChitnisSD and BiesRR. (2014). Modelling the sitagliptin effect on dipeptidyl peptidase-4 activity in adults with haematological malignancies after umbilical cord blood haematopoietic cell transplantation. Clin Pharmacokinet, 53:247–259.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
